CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
[18F]Florbetapir PET imagingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01767493
NCT01767493Phase 4Completed
CompareCT.gov

An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis

Institute for Neurodegenerative Disorders·interventional·Posted Jan 14, 2013·Updated Aug 30, 2021

In Brief

A Phase 4 clinical trial evaluating [18F]Florbetapir PET imaging for Multiple Sclerosis. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the feasibility of \[18F\]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsBiogen

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2013
Enrollment StartNov 1, 2012
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.5 years ago

Interventions

[18F]Florbetapir PET imagingdrug

\[18F\]Florbetapir and PET imaging